Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Montserrat, E.
Right arrow Articles by Rozman, C.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Montserrat, E.
Right arrow Articles by Rozman, C.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 8:S93-S101, 1997
© 1997 European Society for Medical Oncology

B-cell chronic lymphocytic leukemia: Recent progress in biology, diagnosis, and therapy

E. Montserrat, F. Bosch and C. Rozman

Postgraduate School of Hematology ‘Farreras Valenti’, Department of Medicine, University of Barcelona, Hospital Clinic Barcelona, Spain

1Correspondence to: E. Montserrat MD Hematology Service & Postgraduate School of Hematology ‘Farreras Valenti’ Department of Medicine Hospital Clinic Villarroel, 170-08036 Barcelona Spain

B-cell chronic lymphocytic leukemia (CLL) is a highly common form of leukemia characterized by the accumulation of long-lived, functionally inactive, mature appearing neoplastic B lymphocytes. In addition, immune disturbances such as hypogammaglobulinemia and autoimmune phenomena (particularly, autoimmune hemolytic anemia) are frequently found in CLL patients [1–2]. The etiology of CLL is unknown. In contrast with other leukemias, there is no relationship between CLL and exposure to radiation or other cytotoxic agents. A genetic basis is highly likely since there are differences in the incidence of CLL in different countries (e.g., CLL accounts for 30%–40% of all the leukemias in Western countries as compared to 5%–10 in Asian countries) and the risk of contracting CLL is higher among persons with first-degree relatives with the disease [3]

Because the incidence of CLL increases with age and the longer life expectancy of the general population, the age of patients at diagnosis is increasing. The median age at diagnosis is now about 70 years, with only one-third of the patients being less than 60 years of age. In the majority of the series, males predominate over females in a proportion of 1.5/1. The prognosis of patients with CLL is variable. However, clinical stages and other prognostic factors allow the individual risk of each patient to be assessed very accurately, which is useful for making treatment decisions.

In the past two decades, significant progress has been made in CLL [4–10]. This review summarizes recent advances in the biology, diagnosis, and therapy of CLL.

B-cell chronic lymphocytic leukemia, CLL biology, CLL diagnosis, CLL therapy


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.